Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly rC1INH prophylaxis in asymptomatic hereditary C1INH deficiency (HAE)
2009-010736-18Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHP623 in hereditary angioedema (HAE), sponsored by Pharming Group. Primary endpoint: Frequency of breakthrough attacks of HAE. Started Apr 2009; status: completed.
02
Drugs
SHP623
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2009-010736-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010736-18.